Abstract: The ecology of infectious disease in wildlife has become a pivotal theme in animal and public health.
INTRODUCTION
Globally, emerging infectious diseases represent a threat to human and animal health (Daszak et al. 2000; Woolhouse et al. 2008) . Most emerging diseases originate from wildlife (Taylor et al. 2001) , where they may infect multiple animal hosts (Haydon et al. 2002) . Understanding disease emergence requires consideration of the pathogen, animal hosts that are naturally infected by the pathogen and the ecological interactions which facilitate pathogen perpetuation in nature (Childs et al. 2007 ). The One Health concept recognizes that human, domestic animal, and wildlife health are interconnected and should be considered within an ecosystem context (Kaplan et al. 2009 ), while promoting collaboration between microbiologists, ecologists, epidemiologists, physicians, veterinarians, and modelers in the development of conceptual and mathematical system models. Models can guide appropriate disease surveillance, prevention, and control strategies (Fooks 2007; Zinsstag et al. 2009 Zinsstag et al. , 2011 . Communication between these traditionally independent disciplines relies on a mutual conceptual understanding of disease surveillance methods and precise interpretation of the data generated. Subsequent data use in predictive models must recognize the strengths and limitations of the techniques utilized (Table 1) . This paper presents concepts and examples that may appear obvious to immunologists and microbiologists, yet may be unknown, or overlooked by, ecologists, modelers, and policy makers.
The measurement of antibodies in blood is a critical disease surveillance tool because antibodies are typically easier to detect and persist longer than the inciting infectious agents. Serological assays detect antibodies induced by infection or vaccination, and provide evidence of past exposure to a pathogen. Although ecologists, modelers and policy makers may receive little training in immunology or the technical aspects of measuring host immune response to infection, they often must rely on serological data for inference to pathogen force of infection and transmission rates, as well as to parameterize dynamic disease models. Here we review the role of antibody assays and the interpretation of results in wildlife disease investigations, for an audience with little training in immunology or laboratory diagnostics. We discuss common factors that lead to misinterpretation of serological data, which primarily result from a lack of understanding about host immune response to infection and variation in test sensitivity and specificity. We address issues relating to the interpretation of antibody prevalence data from wildlife, and provide recommendations to guide study design and inference using serologic data (Table 2) .
APPROACHES TO STUDYING WILDLIFE INFECTIONS
Incidence and prevalence are the most frequently used measures to describe the epidemiology of infection in natural populations. Incidence is the number of new infections in a population-at-risk over time. Prevalence can be described as point or period, with the former describing the proportion of infected animals in a population at any particular moment, and the latter describing the proportion of infected animals in a population over a designated period of time (e.g., season). Antibody prevalence (i.e., seroprevalence) describes the proportion of individuals within a population that demonstrate pathogen-specific antibodies in the serum. Longitudinal or cross-sectional sampling strategies gather data on incidence and prevalence to infer temporal or spatial infection dynamics in wildlife populations.
Longitudinal studies repeat sampling of individuals, social groups, or populations, to detect changes in antibody prevalence over time, and may be used to estimate infection incidence if the sample size is large enough to detect antibody seroconversion events in the population (Hazel et al. 2000) . Re-sampling individual wild animals, however, is often logistically difficult, therefore where it is possible to determine age in a species, age-structured antibody prevalence data may be utilized to gain insight into pathogen transmission processes (Farrington et al. 2001) . However, insights can be limited by available knowledge regarding individual serological outcomes to infection (Evans 1976) , including the: probability that an infected individual will seroconvert; incubation period and case fatality rate of infected individuals; duration of the antibody response to infection; and relationship between antibody status and resistance to pathogen infection. Often, few data exist regarding these fundamental questions and models generated from antibody prevalence data should recognize such uncertainties.
Cross-sectional studies focus on the social group, population, or species and, in contrast to longitudinal studies, provide snapshots on current or past infection prevalence rather than incidence. Antibody prevalence is only equivalent to infection incidence when the duration of tested antibody is orders of magnitude shorter than life-span of the host (e.g., IgM responses). Cross-sectional studies can document evi- Bats may maintain lyssavirus neutralizing antibodies from months to years with no active infection (Shankar et al. 2004; Kuzmin et al. 2008) .
Antibody positive animals are protected against re-infection
The relationship between immunity and infection resistance depends on the type of antibody detected (e.g., binding or neutralizing) and the disease system. Generally speaking, detectable antibody does not indicate protection.
Measles antibodies generally confer life-long resistance to infection.
With influenza, antibodies are frequently crossreactive to circulating strains, yet are not necessarily protective against infection with those strains.
A well validated test in one species can also be used to directly infer antibody status in another species
Validation should be species, and ideally population, specific.
No exceptions to this rule exist. One of the few international systems where attempts have been made successfully to ensure between lab standardization is for rabies virus serological assays (Robardet et al. 2011 ).
The area where there has probably been most work is with influenza, where standardization is unreliable (Wood et al. 1994 ).
All tests are highly specific (accurately able to identify negative results and avoid false positives) and highly sensitive (accurately able to identify positive results and avoid false negatives).
False negatives and positives do occur and few assays have been properly validated for use with any of the diversity of wildlife species.
Low specificity: Horton et al (2010) quantified cross-reactivity between lyssaviruses. Infection with one lyssavirus can induce antibodies that react to others. Low sensitivity: Turmelle et al (2010b) show that neutralizing antibodies against rabies virus may be undetected in bats despite prior exposure and demonstrated immunity to infection.
Interpretation of antibody testing results is the same in all populations
The ability to detect true positives (i.e., positive predictive value-PPV) for a test in a given population depends on the prevalence of antibody or infection in that population. Whenever possible, the specificity, sensitivity
and PPV of a test should be evaluated using a collection of reference samples that mirror the suspected prevalence in the wildlife population.
In populations where antibody and/or infection prevalence is low, positive results are more likely to be false positives than in populations where prevalence is high, driven by test specificity. If infection is common and test sensitivity low, then negative results are more likely to be false. Seronegative population equals no infection, and seronegative individuals are naïve.
The duration of the antibody response may vary by host-pathogen system, but antibody titers generally wane over time following infection.
High infection-associated mortality complicates detection of antibody-positive animals. Infection dynamics may fluctuate seasonally or annually. Turmelle et al (2010b) clearly show that the induction of antibodies to rabies virus in bats may depend on the viral infection dose and antibody levels may drop below detection levels in animals that seroconvert following infection. Rabies virus and herpesviruses may evade host immune detection, and thus seronegative animals may be infected.
Serological tests can differentiate vaccinated and infected individuals
In the majority of cases this is not possible, but in specific situations vaccines or serological tests have been designed to differentiate immunization from infection.
Antibodies to non-structural proteins (NSPs) are not usually elicited following vaccination with inactivated products. DIVA (differentiating infected from vaccinated animals) vaccines rely on detection of antibodies to NSPs, but such assays are generally unavailable.
You can infer timing of infection from magnitude of antibody titer
Antibody responses are highly variable between individuals, dynamic over time and vary significantly between primary and secondary infections (where anamnestic responses occur).
Validated assays against IgM antibody can be used to infer recent timing, but this is unusual. Host or environment specific factors can also limit the strength of an antibody response, precluding reliance on magnitude of titer to infer timing or dose of infection.
dence for circulation of a pathogen within a group, population, geographic area, or species; for example, during exploratory or outbreak investigations when the infection status of a population, or the natural host range of a pathogen, is unknown (Swanepoel et al. 2007; Lembo et al. 2011) . A major limitation of single cross-sectional studies is that they do not provide information on infection dynamics. However, cross-sectional antibody prevalence data may still be useful for disease ecology studies, and in some cases more useful than infection prevalence data (Heisey et al. 2006) . For example, antibodies typically persist longer than antigen, and hence are more likely to be detected within a population 'snapshot'. Repeated cross-sectional surveys that incorporate age-structured sampling may permit inference into temporal infection dynamics of wildlife (Plowright et al. 2008; Hayman et al. 2012 ). Cross-sectional surveys can also be used to evaluate spillover risk from wildlife populations. For example, crosssectional surveys of antibodies to Brucella abortus in elk or to pseudorabies virus in wild swine inform managers where spillover to livestock is most likely to occur, and hence where to target management (Cross et al. 2007; Pannwitz et al. 2011) . Serology has also been used to evaluate risk of spillover from domestic animals to wildlife, as with canine distemper virus transmission from domestic dogs to Serengeti carnivores (Alexander and Appel 1994; Cleaveland et al. 2000) . Cross-sectional antibody data are important in planning and evaluating wildlife disease management strategies. For example, vaccination against rabies virus (RABV) is undertaken annually in North America and Europe through the use of recombinant or modified live virus vaccines, enclosed in a bait for oral consumption by target wildlife ). Cross-sectional surveys are used to determine the pre-intervention spatial distribution of immunity so that vaccine baits can be optimally distributed (Vos 2003) , and post-vaccination herd immunity for inference to bait uptake and infection resistance (Sidwa et al. 2005) . RABV vaccination and modeling of immunity were management strategies also used to prevent the extinction of the Ethiopian wolf (Canis simiensis) (Haydon et al. 2006; Knobel et al. 2008) . Another example involves management of bovine tuberculosis (Mycobacterium bovis) spillover to cattle through Bacillus Calmette-Guérin (BCG) vaccination of a wildlife reservoir, the European badger (Meles meles), in Great Britain (Chambers et al. 2011) . Discrimination of infected versus vaccinated badgers was possible in this study (Greenwald et al. 2003) , though it is typically not possible with antibody prevalence data.
A valuable step in designing ecological wildlife disease investigation involves the development of a conceptual, and ideally quantitative and predictive epidemiological model of the system. Early communication and collaborative model development ensure that appropriate data will be collected to inform a predictive model of the system (Table 2) . Traditional epidemiological models identify the basic compartments which formally define cohorts of susceptible, exposed, infected and (perhaps) recovered or immune individuals (i.e., SEIR), and the 1. Investigations of wildlife disease should be developed from a conceptual, and ideally quantitative, model of the study system. Early and continual communication with disease experts and diagnosticians in the specific field is imperative for consideration of the optimal test(s) employed, along with associated strengths and limitations for the purpose of study. 2. Full biological information from sampled animals (i.e., locality, species, age, sex, reproductive status) should be collected and reported, and ideally, longitudinal investigations should be conducted rather than cross-sectional studies, with an emphasis on age-structured sampling. 3. Extreme care should be taken to optimize sample quality prior to testing, including sterile technique, maintenance of proper cold chain and storing multiple aliquots of a sample. Similarly, although difficult in many wildlife studies, all samples collected for a study should be handled in an identical manner across study locations and years. 4. Whenever possible, all samples should be processed by the same operator using identical positive and negative controls. Otherwise, all samples should be tested within the same test run. 5. Full reporting of test methodology and results are critical to allow comparisons with other studies, including a description of precise protocols or modifications employed, including cut-offs, controls and confidence intervals for antibody prevalence estimates. 6. Where possible, results from one type of assay should be confirmed using an alternative test. 7. In the absence of demonstrating that a specific pathogen strain used in a test also occurs in the population sampled, or in systems where cross-reactivity has been demonstrated, consider the possibility of cross-reactivity with other pathogens or strains of the pathogen of interest. 8. Caution in interpretation should be exercised when antibody titers of individuals in a population are very low.
interactions among these cohorts which facilitate the invasion and maintenance of a pathogen in animal or plant populations May 1979, 1986) . To parameterize these models, knowledge of the actual infection status of animals, and how this changes over time, is required. Acquiring these data could involve the lethal sampling of large numbers of animals, particularly if infection incidence is low. As this usually is neither feasible nor ethical, antibody data are used as a proxy for prevalence of infection.
Serological data may be more useful than infection prevalence data in determining the force of infection-the rate at which susceptible individuals become infected and the foundation for estimating transmission rates (Heisey et al. 2006) . If antibody loss is slow and disease-induced mortality is well understood (Heisey et al. 2006 (Heisey et al. , 2010 , serology as an indicator of past infection may be more easily interpreted than prevalence data. For example, a low prevalence could be generated by a high force of infection and fast recovery rate, or a low force of infection and low recovery rate-problems avoided with serology if titers are long-lived.
Factors associated with the infection process, such as pathogen dose, variant and route of inoculation, can all impact the induction of a host antibody response to infection. While detection of antigen-specific antibodies usually indicates prior exposure to a pathogen, negative test results do not necessarily rule out prior exposure (Turmelle et al. 2010b ). Antibodypositive animals are not necessarily infected animals, as one study demonstrated during a survey for Puumala virus in wild bank voles (Clethrionomys glareolus) (Alexeyev et al. 1998) . It is often assumed that the immune class (R) of animals in SEIR models is equivalent to seropositive animals, when in fact antibodies may not be a reliable indicator of infection resistance (Raberg et al. 2009 ). In addition, variation in the sensitivity of antibody detection methods may exist (Cleaveland et al. 1999; Chambers et al. 2002; Troyer et al. 2005) , with apparent trade-offs between sensitivity (ability to identify positive results and avoid false negatives) and specificity (ability to identify negative results and avoid false positives) for any assay. However, application of novel modeling methodologies, such as site-occupancy models, may tolerate imperfect detection probabilities based on serosurveys and other diagnostic techniques (Lachish et al. 2012) .
DETECTING INFECTIONS IN WILDLIFE
The objective of disease surveillance systems is to track the incidence and prevalence of a specific pathogen infection in populations of interest. Several diagnostic techniques can obtain such data, each having its own strengths and limitations (OIE 2010) . Pathogen isolation (e.g., using cell culture or animal models) permits identification and characterization of the disease agent, and enables animal infection experiments which are necessary to fulfill Koch's postulates (Evans 1976) and characterize host pathogenesis. Pathogen isolation also permits a greater epidemiological understanding of the circulating pathogen diversity within and among reservoir and incidental hosts (Streicker et al. 2010 ). However, pathogen isolation from wildlife can be challenging even under ideal laboratory conditions. Infection burdens may be low, as observed with henipavirus infections in bats (Middleton et al. 2007; Halpin et al. 2011) , or the pathogen may be sequestered in organs, thereby requiring lethal sampling, as with brucellosis in bison (Bison bison) and elk (Cervus elaphus) (Baldwin and Roop 2002) or classical swine fever in wild swine (Sus scrofa) (Kaden et al. 2006) . Some infections may be latent, i.e., dormant in the body but with potential for reactivation, as has been observed with pseudorabies in wild swine (Wittmann and Rziha 1989) . Often, animal infectious periods are short, as seen with RABV and canine distemper virus (Deem et al. 2000; Hampson et al. 2009 ), with few animals infected at any given time, thereby requiring very large sample sizes to detect infection. Finally, the handling and isolation of some pathogens requires high containment facilities only found in specialist laboratories. These factors might make obtaining isolates from wildlife impractical in many cases.
Direct pathogen detection tests, other than isolation, such as antigen-detection assays and molecular diagnostic tools (e.g., the polymerase chain reaction-PCR), can be used to detect evidence of active or latent infection. These methods share many of the limitations of pathogen isolation: unless a pathogen is circulating in blood, excreted in urine or feces, or colonizing an accessible mucosal surface or superficial lymph node, lethal sampling of wildlife will be required. Despite this, detection of host pathogen excretion via accessible pathways (e.g., blood or mucosal surfaces) can provide meaningful insights for parameterizing transmission probabilities and rates, although several studies also recognized that pathogen excretion may be intermittent among infected animals (Baer and Bales 1967; Chambers et al. 2002; Middleton et al. 2007 ), potentially limiting inference from cross-sectional snapshots. However, sample integrity is a key factor for field studies and maximizing the probability of successful pathogen isolation or detection often requires cold-chain or laboratory capacity that is difficult in a field setting, especially in remote geographic areas.
Given some limitations of pathogen isolation and antigen detection methods, antibody prevalence data are often used to elucidate infection dynamics in animal populations. The presence of specific antibody, however, only demonstrates past exposure to an antigen, while typically providing no information about the timing, intensity or frequency of infection. At a population level, antibody prevalence data provide information about the cumulative exposure history of the population, but not necessarily infection status. Antibody prevalence does not change quickly in response to changes in infection incidence, particularly when antibodies persist for long periods and host population turnover is slow. Some pathogens have evolved strategies to circumvent detection by the host immune system (e.g., lyssaviruses and herpesviruses) (Aleman et al. 2001; Faber et al. 2002; Wang et al. 2005) , thus complicating the reliance on serological techniques to track infection dynamics. Notable testing limitations with serological techniques include cross-reactivity, poor accuracy, and undefined or non-standardized cut-off values to interpret an antibody-positive result. Because presence of antibody may not confer infection resistance, it is critical to explore the significance of an antibody-positive status in the context of a controlled infection process, using in vitro and in vivo models. However, with careful study design and interpretation (Table 2), antibody prevalence can be an invaluable tool for understanding the ecology of disease dynamics, even in poorly-understood systems such as wildlife populations.
OPTIMAL TEST SELECTION AND INTERPRETATION
The two main classes of antibody targeted in serological testing are IgM and IgG, where IgM is secreted first in response to pathogen infection yet is usually short-lived, whereas IgG is secreted later and persists longer in the circulation. Serological assays typically detect either binding (BAb) or neutralizing antibodies (NAb), and the type of test determines the type of antibodies that are detected and the subsequent inference that is possible from such data ( Table 3) .
Regardless of the assay selected, proper test validation, and stringent laboratory quality control standards are key to reliable collection and interpretation of antibody prevalence data (OIE 2010) . Standard practice requires that appropriate positive and negative controls (ideally, relevant to the host population sampled) be employed in every test. Although laboratory strains of a pathogen may be employed for assay standardization, a field-derived strain of the pathogen may be more appropriate for certain systems or questions. Where pathogen diversity within a population, species or community is high, e.g. paramyxoviruses among bats (Drexler et al. 2012) , it may be desirable to include multiple pathogen strains in serological tests (Kuzmin et al. 2011) . The recent development of pathogen pseudotypes for serologic testing can facilitate testing of diverse pathogen repertoires using small sample volumes while minimizing biohazards (Temperton et al. 2005; Wright et al. 2008 ).
Cross-reactivity of antibodies to multiple pathogens has been important in vaccine development, but can also limit the interpretation of antibody prevalence data (Weyer et al. 2008; Horton et al. 2010; Mansfield et al. 2011 ). Cross reactivity can pose particular challenges in disease investigations of wildlife, as there is often no prior characterization of circulating pathogen diversity or cross-reactivity within and among populations. For example, antisera raised against one flavivirus can cross-react with other flaviviruses (Mansfield et al. 2011) , but cross-reactivity within and between flavivirus serocomplexes has been inconsistent (Calisher et al. 1989a) . One consequence of flavivirus crossreactivity is reduced specificity in serological assays (Hirota et al. 2010) , which led to the early misdiagnosis of the North American West Nile Virus epidemic as St. Louis Encephalitis in New York City (Lanciotti et al. 1999; WHO 1999) . However, the idea of cross-reactivity limiting the specificity of serological assays extends to a variety of systems, as demonstrated among rhabdoviruses (Calisher et al. 1989b) .
Evaluation of test repeatability and robustness is necessary for sound interpretation of serological test results, particularly for longitudinal studies. Inter-laboratory variation is a wellrecognized issue for all pathogen testing, but some assays, particularly virus neutralization tests (VNTs), are prone to variation even within the same laboratory. This is because they are biologically dynamic tests, relying on consistent replication of live virus populations in cell culture. The NAb titer of a single control serum tested against a standard laboratory strain of RABV in a closely controlled test can vary by more than twofold (Figure 1 ). The precise quantity of virus used in neutralization assays affects estimated antibody titers. To counter this, acceptable standards of variation must be developed with regard to positive and negative controls, with any test results that do not fall within strict and pre-determined values being discarded. Although frequently not performed, longitudinal samples from individuals should be tested in the same assay at the same time, rather than in consecutive assays.
Within and between assay-and between laboratoryvariation has been carefully evaluated for serological assays in influenza, particularly in humans in relation to vaccination (Wood et al. 1994 ), but also for horses (Mumford 2000) . When considering the two most commonly used and well-controlled serological assays available for human influenza, hemagglutination inhibition (HI) and single radial hemolysis (SRH) assays, Wood et al (1994) reported that although each technique was reproducible within laboratories, variability between laboratories was higher for HI (maximum variability 32-fold; geometric coefficient of variation, GCV, 112%) than for SRH (maximum variability 3.8-fold; GCV 57%). The potential for such variation is usually overlooked when interpreting serological data.
To determine population antibody prevalence and to evaluate the sensitivity and specificity of a test, values obtained with a given test sample are evaluated against a reference cut-off value, meaning that all values below the cut-off are considered antibody-negative and all values above the cut-off value are considered antibody-positive. Standard cut-off values are often not known, usually due to a lack of well-characterized reference samples from target wildlife populations. Modification of a cut-off value has a direct impact on the sensitivity and specificity of the serological assay-and hence estimated antibody prevalence. For this reason, it can be difficult to compare serological results across studies, particularly as cut-off values usually are not standardized between laboratories and because many publications report only proportional antibody prevalence rather than individual titers. Comparisons are more difficult when pathogen strains or antigens used in a serological test vary across studies. Estimating antibody prevalence is most problematic with regards to the evaluation of low-titer individuals and their proportion within a population, such that reporting results as quantitative values may be more informative (Peel et al. 2012 ).
An example of how different criteria can affect interpretation of results involves the testing of 166 European bats for European bat lyssavirus (EBLV) NAb. Using the same cut-off threshold for a positive response (i.e., a 1:27 dilution), but a different level of virus neutralization (100% versus 50% reduction in fluorescing fields) can lead to variation in NAb prevalence estimates, ranging from 0.6% (CI 0.0-3.3) under more stringent criteria (i.e., 100% neutralization) to 4.8% (CI 2.1-9.3) under less stringent criteria (i.e., 50% neutralization) (AVHLA, unpublished data). Similarly, in a study of RABV NAb among sera collected over two years from 1,058 bats in the United States, an increase in test cut-off threshold from 0.06 international units per ml (IU/ml) to 0.1 IU/ml led to a reduction in RABV NAb seroprevalence from 38% (CI 35-41) to 28% (CI 25-31) (CDC, unpublished data). While variation in testing conditions can be accounted for by using reference positive control sera of known potency, the above examples highlight the difficulties in running longitudinal samples across different years or operators and demonstrate that different estimates of antibody prevalence from the same samples are possible. Instances where positive control sera are not included or reported are especially troubling, and make it difficult to control for test variation across operators or laboratories. Efforts must be made to standardize methods and result interpretation and reporting across laboratories.
SEROLOGICAL INTERPRETATION IN WILDLIFE POPULATIONS
In most systems, the duration of detectable antibody following infection is not known. While positive reactions for one antibody class (i.e., IgM) can be taken as evidence of active or recent infection, it is not possible to infer timing of infection from more commonly detected antibody classes shows a 0.18 log 2 reduction in serum titer for every twofold increase in virus titer and substantial variance in serum titer (standard deviation 0.42 log 2 ). Virus titer is measured for each test, and results are discarded if the infectious dose is outside pre-determined limits (4.32-8.23 log 2 median tissue culture infective dose-TCID 50 ).
(e.g., IgG). Repeated infection may be necessary to induce an antibody response in some animals (Turmelle et al. 2010b) , and antibodies may persist from weeks to years, depending on the host-pathogen system and individual variation (Aubert 1992) . Importantly, the loss of detectable circulating antibody does not necessarily represent a loss of immunity with respect to subsequent pathogen infection (e.g., memory lymphocytes). Rather, the animal may be primed immunologically to respond to re-infection, or mechanisms such as cell-mediated immunity may also play a significant role in infection resistance. It is typically impossible to know the exposure histories of wild free-ranging animals, particularly during cross sectional studies, and extremely challenging to differentiate seronegative animals that were previously seropositive from animals that have never encountered the pathogen under study (i.e., are truly naïve) ( Table 1) .
With age-structured sampling of mammalian wildlife, maternally-derived antibody (MDAb) may be identified in nursing or recently weaned young, but the function of MDAb in most wildlife host-pathogen systems has not been wellcharacterized (Boulinier and Staszewski 2008) . The presence of MDAb can also interfere with individual immune responses and can compromise the response to vaccination in offspring (Xiang and Ertl 1992; Muller et al. 2001; Siegrist 2003) . Evaluating the proportion of antibody-positive dams is necessary for interpreting proportional antibody prevalence among offspring in a social group or population, as the antibody titer of the dam may impact the probability of transfer to, and the level of MDAb in, respective offspring (Muller et al. 2002; Boulinier and Staszewski 2008; Kallio et al. 2010) . MDAb often wane in juveniles around the time of weaning (Muller et al. 2002; Plowright et al. 2008 ), yet may be detected for a much longer period of time using antibody-binding compared to VNT assays (Muller et al. 2005) . The effects of MDAb may vary across and within host-pathogen systems, and few have been adequately studied. Susceptibility to infection is presumed to be high among offspring nursing from seronegative dams and, where breeding is seasonal, the infection of offspring that are naïve or have waning MDAb may modulate seasonal pulses of infection or disease outbreaks (Fouchet et al. 2007; Kallio et al. 2010; George et al. 2011; Plowright et al. 2011 ). Age-structured serological studies have great potential for providing highly informative insights for disease modeling (Heisey et al. 2006) and disease management strategies (Farrington et al. 2001) , although timing of sampling intervals and proper cohort representation are key considerations.
Despite substantial variation in the longevity of wildlife, the immune response to repeated pathogen infection in long-lived hosts has received little attention. For example, humoral immune responses may be less important following repeated infection of bats with RABV (Turmelle et al. 2010b) , perhaps due to an increasing role of cellmediated defenses (Moore et al. 2006; Horowitz et al. 2010) , potentially complicating a reliance on antibody prevalence data for dynamic disease models in some hostpathogen systems. Certainly, expanding immunological surveillance among wildlife to include different measures of immunity holds exciting promise for modeling the perpetuation and emergence of infectious diseases in wildlife (Graham et al. 2007 ).
Beyond initial decisions about which specific serological test will be employed for a study, sample size and sampling strategy must be carefully considered. Strategies might include capture of free-ranging animals or capture within a roost, shelter, nest or burrow. Capture of refuging animals may bias collection of sick or moribund animals which may be more likely to be infected and seropositive. Comparison of studies investigating RABV NAb seroprevalence in populations of bats suggests different NAb seroprevalence in bats captured while roosting versus those in flight (Constantine et al. 1968; Steece and Altenbach 1989; Turmelle et al. 2010a ). Furthermore, individual immunological response to infection among wildlife populations may vary due to host or environmental factors (Bouma et al. 2010; Graham et al. 2010; Hawley and Altizer 2011) . All studies must consider that age and social structures of populations can vary in space and time, potentially leading to variation in the types of individuals sampled and estimates of antibody prevalence.
CONCLUSIONS
As new diagnostic techniques develop in the study of wildlife disease, the challenges of interpretation of results from all systems are increasing. When properly employed, serological data can be very powerful for inference and modeling of infectious disease dynamics in wildlife, but the limitations must also be acknowledged. Development of conceptual and mathematical models prior to field sampling, greater consideration of pathogenesis and age structure in the population infection process, investment in longitudinal studies whenever possible and standardized sample collection, storage and testing protocols can ensure that reliable and meaningful data are obtained for modeling applications to effectively characterize, and evaluate intervention strategies for, wildlife disease systems. (Fig. 1i ). Once bound (Fig. 1ii) , antibody is subsequently detected using anti-antibody proteins (Fig. 1iii) , often conjugated to an enzyme that fluoresces for detection. Often the serum is diluted prior to testing.
Schematic of antigen-binding assays 1. Western blots (WB) give qualitative results, based on the presence or absence of antibody-antigen binding, detected by electrophoresis and compared to positive and negative controls (Fig. 2) . Occasionally semi-quantitative results are given depending on the strength of the band.
The presence of anti-Ebolavirus antibody (sample number 49) in a serum sample binding to antigen is detected using electrophoresis in a western blot test APPENDIX Table 3 . continued 2. Immunofluorescence tests (IFAT) give qualitative depending on the presence of antibody-antigen binding (Fig. 3) at serial dilutions, and can be used to give quantitative results depending on which dilution(s) the antibodies were detectable.
The presence of anti-antigen antibody in a serum sample detected by an immunofluorescence test 3. Enzyme-linked immunosorbent assays (ELISA, EIA) are by default quantitative. A seropositive result is defined by the strength of color or fluorescence change, indicating the strength of signal and the amount of binding (Fig. 4) , and a threshold is used to decide if it should be classified as positive, in order for qualitative results to be reported. A competitive ELISA is a variation where antigen and antibody are incubated together and conjugated antibody binds unbound antigen, thus a reduction in strength of signal is used.
The presence of fluorescence due to increasing antibody-antigen binding in an ELISA test in this schematic Antibody-function assays and their results Antibody-function assays measure the actions of antibodies for a specific pathway or function. These tests may be used to ''type'' or ''characterize'' the history of infection (e.g., influenza), or as an indirect measure of antibody levels. Sera may be serially diluted. 1. Hemagglutination inhibition and complement fixation assays give qualitative results, based on the presence or absence of hemagglutination, hemagglutination inhibition, or complement fixation, and quantitative results by serially diluting the sera. The presence of hemagglutination, the agglutination of erythrocytes (Fig. 5a ), shown in this 96-well plate (Fig 5b) , demonstrates viral particles are binding to the surfaces of erythrocytes. Antibody in a serum sample would prevent this and quantitative results can be determined by finding the cut-off at which agglutination inhibition ceases.
The presence of hemagglutination, the clustering of red blood cells, shown schematically (a) and in this 96-well plate (b). Table 3 . continued 2. Virus or serum neutralisation tests (VNT/SNT), including those using live or recombinant (e.g., pseudotyped) viruses, measure the capacity of antibody to block a function of the infection, such as cell entry. In such assays serial dilutions of sera are incubated with a standardized ''amount'' of virus, which are then cultured with cells, in eggs, or historically animals. The results are analyzed to determine at which serum dilution a proportion (typically 50% or 100%) of the virus is neutralized. The results are quantitative due to the presence of antibody-antigen binding being detected by fluorescence or reduction in virus induced plaque formation in cells at specific dilutions (Fig. 6a, b) , and/or qualitative based on the presence of antibody-antigen binding, or determined by a cut-off value. Neutralization at lower dilutions (e.g., less than 1:10) is sometimes considered non-specific.
The reduction of plaque forming units is shown across at lower serum dilutions (i.e., 1:10) (a) and the presence of non-neutralized virus is detected by fluorescence in a virus neutralization test (b).The presence or absence of virus at different serum dilutions is used to determine antibody titers and a threshold at which neutralization activity occurs.
